# An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

> **NCT03917719** · PHASE3 · TERMINATED · sponsor: **Catabasis Pharmaceuticals** · enrollment: 130 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Edasalonexent

## Key facts

- **NCT ID:** NCT03917719
- **Lead sponsor:** Catabasis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-14
- **Primary completion:** 2020-10-26
- **Final completion:** 2020-10-26
- **Target enrollment:** 130 (ACTUAL)
- **Why stopped:** The Phase 3 PolarisDMD trial did not meet the primary endpoint. As a result, activities related to the development of edasalonexent have stopped including the CAT-1004-302 Open-Label Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03917719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03917719, "An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03917719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*